SCHEMBL24664301

SCHEMBL24664301

CN(C)N1CCN(c2ccc(Nc3ncc(F)c(-c4cnn(C5CCCC5)c4)n3)cc2F)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK4 P11802 14/20 0.55
▸ CDK6 Q00534 14/20 0.55
▸ CSF1R P07333 12/20 0.55
▸ PIK3CD O00329 6/20 0.55
▸ JAK2 O60674 5/20 0.49
▸ JAK1 P23458 5/20 0.49
▸ FLT3 P36888 4/20 0.49
▸ JAK3 P52333 4/20 0.49
▸ TYK2 P29597 2/20 0.49
▸ CCND3 P30281 2/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ LCK P06239 1/20 0.49
▸ LYN P07948 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ FLT1 P17948 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ FLT4 P35916 1/20 0.49
▸ KCNH2 Q12809 1/20 0.49
▸ CDK9 P50750 2/20 0.48
▸ CCNK O75909 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29607708 0.91 AXL (0.58) CDK4CDK6CSF1RPIK3CDJAK2
SCHEMBL24664302 0.91 AXL (0.58) CDK4CDK6CSF1RPIK3CDJAK2
SCHEMBL29608441 0.90 CDK4 (0.67) CDK4CDK6CSF1RPIK3CDJAK2
SCHEMBL24663782 0.90 CDK4 (0.67) CDK4CDK6CSF1RPIK3CDJAK2
SCHEMBL24663799 0.88 CDK4 (0.51) CDK4CDK6CSF1RPIK3CDJAK2
SCHEMBL29607476 0.88 CDK4 (0.51) CDK4CDK6CSF1RPIK3CDJAK2
SCHEMBL24663778 0.81 FLT3 (0.53) CDK4CDK6CSF1RPIK3CDJAK2
SCHEMBL24663773 0.80 FLT3 (0.52) CDK4CDK6CSF1RPIK3CDJAK2
SCHEMBL29608058 0.77 FLT3 (0.48) CDK4CDK6CSF1RPIK3CDJAK2
SCHEMBL28773800 0.77 FLT3 (0.48) CDK4CDK6CSF1RPIK3CDJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220298140-A1 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF CHENGDU ZENITAR BIOMEDICAL TECHNOLOGY CO., LTD. (CN) 2022-09-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220298140-A1 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF JAK2, FLT3, JAK1 CDK4 17/4885CDK6 92/4885CSF1R 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback